The Food and Drug Administration said that Acadia Pharmaceuticals Inc.'s (NYSE: ACAD) Parkinson's disease hallucination treatment Nuplazid posed substantial safety risk to patients but the stock price surged $3.50 to close at $23.81 ahead of a meeting between a panel of outside experts and Acadia representatives tomorrow.
Acadia Pharmaceuticals to meet with outside experts
March 28, 2016 at 18:30 PM EDT
